A fully integrated pharmaceutical company developing a class of immuno-oncology therapies was in need of a deeper understanding of one of their program’s differentiating attributes. Several indications were under consideration and before further investing in clinical and commercial activities, the sponsor needed to gain insights into available therapies, what drives prescriber decisions, and how their unique approach complimented the existing ‘toolkit’.  Thus, Kineticos was asked to conduct a primary research study intended to understand the viability of the approach as well as how the asset could be positioned in the market post-commercialization.

For the full case study including example deliverables, click here: Portfolio Optimization